We are live on ! Find out more
TSBX

Turnstone Biologics
TSBX

Delisted

TSBX was delisted on the 8th of August, 2025.

Back to rankings

1 hedge funds and large institutions have $0 invested in Turnstone Biologics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

36.28% less ownership

Funds ownership: 36.45% → 0.17% (-36%)

96% less funds holding

Funds holding: 23 → 1 (-22)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $3.03M → $0 (-$3.03M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 22

Holders
1
Holders Change
-22
Holders Change %
-95.65%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$937

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$1.11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$407K
3
BCM
BML Capital Management
Indiana
-$396K
4
TPC
Takeda Pharmaceutical Company
Japan
-$322K
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
– -$1.11M -3,099,265 Closed
Fidelity Investments
2
Fidelity Investments
Massachusetts
– -$407K -1,133,987 Closed
BCM
3
BML Capital Management
Indiana
– -$396K -1,103,386 Closed
TPC
4
Takeda Pharmaceutical Company
Japan
– -$322K -895,824 Closed
Point72 Asset Management
5
Point72 Asset Management
Connecticut
– -$293K -816,923 Closed
7IH
6
72 Investment Holdings
Connecticut
– -$197K -549,980 Closed
Citadel Advisors
7
Citadel Advisors
Florida
– -$75K -208,887 Closed
Geode Capital Management
8
Geode Capital Management
Massachusetts
– -$46.7K -130,077 Closed
DAM
9
Deltec Asset Management
New York
– -$38.1K -106,057 Closed
Vanguard Group
10
Vanguard Group
Pennsylvania
– -$30.1K -83,926 Closed
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
– -$28.5K -79,305 Closed
HF
12
HRT Financial
New York
– -$20K -55,859 Closed
Renaissance Technologies
13
Renaissance Technologies
New York
– -$16.9K -47,100 Closed
GS
14
GTS Securities
New York
– -$16.2K -45,163 Closed
Northern Trust
15
Northern Trust
Illinois
– -$6.61K -18,405 Closed
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
– -$4K -16,430 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$1.7K -4,741 Closed
BlackRock
18
BlackRock
New York
– -$383 -1,066 Closed
JP Morgan Chase
19
JP Morgan Chase
New York
– -$57 -158 Closed
Bank of America
20
Bank of America
North Carolina
– -$54 -150 Closed
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
– -$43 -121 Closed
UBS Group
22
UBS Group
Switzerland
– -$25 -71 Closed
XT
23
XTX Topco
Cayman Islands
– +$937 +2,615 +7%

TSBX Hedge Fund Activity: Q3 2025 in Review

1 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q3 2025, worth a combined $0 — down 100% from $3.03M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of TSBX and 0 opened new positions — a net loss of 22 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was XTX Topco, adding an estimated $937. The largest seller was OrbiMed, exiting entirely with an estimated $1.11M sold.

  • 1 institutional investor held Turnstone Biologics (TSBX) as of Q3 2025, down from 23 in Q2 2025.
  • Funds reported $0 of Turnstone Biologics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Turnstone Biologics positions in Q3 2025 and 22 closed out, a net change of -22 holders.
  • The largest Turnstone Biologics buyer in Q3 2025 was XTX Topco, an estimated $937 added.
  • The largest Turnstone Biologics seller in Q3 2025 was OrbiMed, an estimated $1.11M sold.

Based on aggregated 13F filings for Q3 2025.